Tyrosine kinase inhibitors, such as gefitinib (Iressa ™, ZD1839), block the EGFR. As a result, there is inhibition of cellular proliferation, promotion of apoptosis, and inhibition of anti ...

The majority of people with advanced EGFR-mutant non-small cell lung cancer (NSCLC) receiving first-line osimertinib ...

China’s probe into AstraZeneca Plc has reached its uppermost echelons, ensnaring local president Leon Wang and throwing into question the future of the most successful Western pharmaceutical company ...

or AZ’s Iressa (gefitinib). NICE has ruled that Tagrisso does not meet its end of life criteria, which allows for more flexibility in pricing, as existing drugs are doing enough to prolong ...

EGFR-positive lung cancer is a type of lung cancer with an epidermal growth factor receptor (EGFR) mutation. In the United States, around 10% to 15% of lung cancers are EGFR-positive. Most of these ...

NICE said there is clinical trial evidence showing that Tagrisso stalls cancer growth longer than treatment with two older EGFR drugs, Roche’s Tarceva (erlotinib) and AZ’s Iressa (gefitinib).

A solitary pulmonary nodule (SPN) is an isolated lung growth surrounded by normal tissue. Most SPNs are benign (not cancerous) when they're diagnosed. However, some nodules can enlarge and change over ...

We have summarized in this article the current state of combination therapy of approved targeted drugs and irradiation. Since the introduction of the first targeted compounds almost (trastuzumab ...